Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Consorzio Oncotech745 enrolled

Overview

This is a multi-center, randomized, open-label, parallel group study designed to evaluate efficacy and safety of fulvestrant followed, at progression, by examestane and everolimus versus examestane and everolimus followed, at progression, by fulvestrant in postmenopausal women with HR+ and HER2- LABC or MBC whose disease has progressed to NSAI in the adjuvant or metastatic setting.

In this study everolimus will be administered in combination with exemestane, which is an irreversible steroidal aromatase inactivator that has demonstrated efficacy in the treatment of postmenopausal patients with ABC. Exemestane is indicated for adjuvant treatment of postmenopausal women with HR+ EBC who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy. It is also indicated for the treatment of ABC in postmenopausal women whose disease has progressed following tamoxifen therapy (in the USA) or following antiestrogen therapy (in Europe). In 2011, the BOLERO-2 trial reported (5; 33) a significant benefit for HR+ HER2- postmenopausal pretreated women in the ABC setting by combining everolimus with exemestane. In this randomized, double-blind, placebo-controlled trial a statistically significant improvement in PFS by adding everolimus to exemestane versus exemestane alone was reported. Adding everolimus determined a 2.4-fold prolongation in PFS from 3.2 up to 7.4 months and so lowered the risk of cancer progression by 56% for these women. These findings were confirmed by an independent assessment (4.1 vs. 11.0 months, risk reduction: 64%). The QoL data shows positive trend in the everolimus plus exemestane treatment arm.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

745

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Adult women (≥ 18 years of age) with LABC or MBC not amenable to curative treatment by surgery or radiotherapy, refractory to NSAI 2. Histological or cytological confirmation of ER+ BC and/or PgR+. 3. Postmenopausal women. 4. Radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to randomization 5. Patients must have: * At least one lesion that can be accurately measured in at least one dimension ≥ 20 mm with conventional imaging techniques or ≥ 10 mm with spiral CT or MRI * Bone lesions: lytic or mixed (lytic + sclerotic) in the absence of measurable disease as defined above. 6. Adequate bone marrow and coagulation according RCP 7. Adequate liver function, according RCP 8. Adequate renal function, according RCP 9. ECOG Performance Status ≤ 2 10. Written informed consent Exclusion Criteria: 1. HER2-overexpressing patients by local laboratory testing (IHC3+ staining or in situ hybridization positive). 2. Patients who received chemotherapy for MBC 3. Patients who received more than one NSAI treatment for LABC or MBC 4. Pre-menopausal, pregnant, lactating women. 5. Known hypersensitivity to mTOR inhibitors 6. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption. 7. Radiotherapy within four weeks prior to enrollment 8. Currently receiving hormone replacement therapy, unless discontinued prior to enrollment. 9. Patients receiving concomitant immunosuppressive agents or chronic corticosteroids use, at the time of study entry except in some cases 10. Patients with symptomatic visceral disease in need of urgent disease control 11. Symptomatic brain or other CNS metastases. 12. Patients with a known history of HIV seropositivity. 13. Active, bleeding diathesis, or on oral anti-vitamin K medication (except cases). 14. Any severe and / or uncontrolled medical conditions such as: * Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤6 months prior to enrollment, serious uncontrolled cardiac arrhythmia * Uncontrolled diabetes as defined by fasting serum glucose \> 1.5 × ULN * Acute and chronic, active infectious disorders * Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study treatments (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome) * Inability to swallow oral medications * Significant symptomatic deterioration of lung function. 15. Hepatic-related exclusion criteria: * History of liver disease, such as cirrhosis or chronic active hepatitis B and C. * Presence of Hepatitis B surface antigen (HbsAg) and/or of Hepatitis B Virus - Deoxyribonucleic acid (HBV-DNA) * Presence of anti-HCV and/or HCV-RNA-PCR * History of, or current alcohol misuse/abuse within the past 12 months * Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A within the last 5 days prior to enrollment. * History of non-compliance to medical regimens. * Patients unwilling to or unable to comply with the protocol 16. Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A 17. History of non-compliance to medical regimens. 18. Patients unwilling to or unable to comply with the protocol. Screening for hepatitis B Prior to enrollment, peculiar patients should be tested for hepatitis B viral load and serologic markers, that is, HBV-DNA, HBsAg, HBsAb, and HBcAb: Screening for hepatitis C Patients with any of the following risk factors for hepatitis C should be tested

Outcomes

Primary Outcomes

Progression-free survival (PFS1)

The number of events required for the other primary endpoint (PFS1), and the expected time needed to achieve it are derived from previous calculations. Assuming an average accrual rate of 31 pts/month (677pts/22 months), a median PFS1 of 6 months in the Fulvestrant arm (control), a Hazard ratio of 0.70 (implying that a median PFS1 of 8,6 months is expected in the experimental arm, a 2-sided significance level of 0.025 and power of 0.90, 391 events are required for PFS1, that will be achieved in about 22 months (East 6 software).